Cryoport, Inc. (NASDAQ:CYRX) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants Todd Fromer - President, KCSA Strategic Communications Jerrell Shelton - CEO Robert Stefanovich - CFO Mark Sawicki - CSO Conference Call Participants John Sourbeer - UBS Brandon Couillard - Jefferies Michael Jones - SVB Securities Joseph Conway - Needham & Co. Paul Knight - KeyBanc David Larsen - BTIG Yuan Zhi - B. Riley Securities Jacob Johnson - Stephens Operator Thank you for standing by. This is the ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______. Commission File Number: 001-34632 CRYOPORT, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 88-0313393 (St ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ⌧ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-34632 CRYOPORT, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 88-0313393 (State or other juris ...

Cryoport, Inc. (NASDAQ:CYRX) Q4 2021 Earnings Conference Call February 24, 2022 5:00 PM ET Company Participants Todd Fromer - President, KCSA Strategic Communications Jerrell Shelton - Chief Executive Officer Robert Stefanovich - Chief Financial Officer Dr. Mark Sawicki - Chief Scientific Officer Thomas Heinzen - Vice President, Corporate Development and IR Conference Call Participants Michael Jones - SVB John Sourbeer - UBS David Saxon - Needham & Co. Brandon Couillard - Jefferies David Larsen - BTIG Opera ...

Cryoport, Inc. (NASDAQ:CYRX) Q3 2021 Earnings Conference Call November 4, 2021 5:00 PM ET Company Participants Todd Fromer – President, KCSA Strategic Communications Jerrell Shelton – Chief Executive Officer Mark Sawicki – Chief Scientific Officer Robert Stefanovich – Chief Financial Officer Thomas Heinzen – Vice President of Corporate Development and Investor Relations Conference Call Participants John Sourbeer – UBS Chad Wiatrowski – SVB Leerink Matt Andrews – Jefferies Paul Knight – KeyBanc David Larsen ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______. Commission File Number: 001-34632 CRYOPORT, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 88-0313393 ...

Cryoport, Inc. (NASDAQ:CYRX) Q2 2021 Earnings Conference Call August 5, 2021 5:00 PM ET Executives Todd Fromer - Managing Partner-KCSA Jerrell Shelton - Chairman, President and Chief Executive Officer Robert Stefanovich - Chief Financial Officer, Treasurer and Corporate Secretary Mark Sawicki - Chief Scientific Officer Thomas Heinzen - Vice President-Corporate Development & Investor Relations Analysts Matt Andrews - Jefferies Andrew D'Silva - B. Riley Securities David Larsen - BTIG Jacob Johnson - Stephens ...

Market Overview - The global cell and gene therapy (C&GT) market was valued at approximately $4.2 billion in 2019 and is projected to grow to over $33.1 billion by 2024[210]. Clinical Trials and Support - As of the end of Q2 2021, the company supported 561 clinical trials and seven commercial therapies, with expectations of up to 11 additional submissions for Cryoport-supported products in the second half of 2021[211]. - The number of clinical trials supported increased to 561, with 69 Phase III trials as of June 30, 2021, indicating growth in biopharmaceutical activities[260]. Acquisitions and Strategic Alliances - The acquisition of CRYOPDP expanded the company's global presence to 27 supply chain centers in 13 countries, enhancing its capabilities in temperature-controlled logistics solutions[224]. - The acquisition of MVE Biological Solutions strengthens the company's position in the biopharma/pharma markets and secures its supply of cryogenic shippers and biostorage equipment[225]. - The company aims to continue pursuing targeted acquisitions to enhance its market leadership and broaden its capabilities[217]. - The company has established strategic alliances with major logistics providers such as FedEx, DHL, and UPS to integrate its solutions into their services[215]. Revenue and Financial Performance - Total revenues increased by $46.8 million, or 498.5%, from $9.4 million to $56.2 million for the three months ended June 30, 2021, compared to the same period in 2020[237]. - Service revenues increased by $20.3 million, or 216.1%, from $9.4 million to $29.7 million for the three months ended June 30, 2021, driven by the acquisition of CRYOPDP[238]. - Product revenues were $26.5 million for the three months ended June 30, 2021, primarily due to the acquisition of MVE Biological Solutions[239]. - Revenue from the biopharma/pharma market increased by $36.9 million, or 431.0%, from $8.6 million to $45.5 million for the three months ended June 30, 2021[241]. - Total revenues increased by $90.3 million, or 471.3%, from $19.2 million to $109.5 million for the six months ended June 30, 2021, compared to the same period in 2020[256]. - Service revenues increased by $37.3 million, or 194.5%, from $19.2 million to $56.4 million for the six months ended June 30, 2021, driven by the acquisition of CRYOPDP[257]. - Product revenues were $53.0 million for the six months ended June 30, 2021, primarily due to the acquisition of MVE Biological Solutions[258]. Expenses and Margins - Gross margin for the three months ended June 30, 2021 was 45.2% of total revenues, compared to 54.6% for the same period in 2020[244]. - Selling, general and administrative expenses increased by $15.7 million, or 173.5%, compared to the first quarter of 2020, primarily due to acquisitions[248]. - Gross margin for the six months ended June 30, 2021 was 45.6% of total revenues, down from 54.2% for the same period in 2020[263]. - Selling, general and administrative expenses increased by $29.9 million, or 185.5%, compared to the same period in 2020, primarily due to acquisitions and infrastructure expansion[267]. Cash Flow and Investments - As of June 30, 2021, the company had cash and cash equivalents of $60.4 million and $289.1 million in short-term investments, with working capital of $373.6 million[280]. - Net cash used in investing activities was $246.3 million during the six months ended June 30, 2021, primarily due to the acquisition of CTSA and F-airGate and the purchase of short-term investments[282]. - Net cash provided by financing activities totaled $273.3 million during the six months ended June 30, 2021, mainly from net proceeds of $269.8 million from a public offering of common stock[283]. Future Outlook and Risks - The company recognizes potential need for additional capital to fund future acquisitions, which may involve equity and/or debt funding sources[284]. - Foreign exchange risk related to cash and cash equivalents of $18.1 million could result in declines of $0.9 million, $1.8 million, and $3.6 million under adverse changes of 5%, 10%, and 20% respectively[289].

Market Growth and Trends - The global cell and gene therapy (C&GT) market was valued at approximately $4.2 billion in 2019 and is projected to grow to over $33.1 billion by 2024[210]. - The biopharma/pharma market has over 1,200 global clinical trials underway in 2021, highlighting the growing demand for temperature-controlled supply chain solutions[228]. Company Performance and Financials - Total revenues increased by $43.5 million, or 445.2%, from $9.8 million to $53.3 million for the three months ended March 31, 2021, compared to the same period in 2020[236]. - Service revenues rose by $17.0 million, or 173.8%, from $9.8 million to $26.8 million for the three months ended March 31, 2021, driven by the acquisition of CRYOPDP[237]. - Product revenues were $26.5 million for the three months ended March 31, 2021, primarily due to the acquisition of MVE Biological Solutions[238]. - Revenue from the biopharma/pharma market increased by $33.6 million, or 382.5%, from $8.8 million to $42.4 million for the three months ended March 31, 2021[240]. - Revenues in the reproductive medicine market increased by $1.1 million, or 148.4%, from $0.8 million to $1.9 million for the three months ended March 31, 2021[242]. - Gross margin for the three months ended March 31, 2021, was 46.1% of total revenues, compared to 53.8% for the same period in 2020[243]. - Organic revenue increased by $3.5 million, or 35.3%, to $13.2 million for the three months ended March 31, 2021[236]. - Adjusted EBITDA for the three months ended March 31, 2021, was $6.978 million, compared to a loss of $1.770 million in the same period in 2020[258]. Operational Developments - As of the end of Q1 2021, the company supported 543 clinical trials and seven commercial therapies, with expectations for up to 21 additional C&GTs to file for regulatory approval in 2021[211]. - The number of clinical trials supported increased to 543, with 69 Phase III trials as of March 31, 2021[240]. - The company expanded its global presence to a network of 27 supply chain centers in 13 countries following the acquisition of CRYOPDP in October 2020[224]. - The acquisition of MVE Biological Solutions enhances the company's capabilities in cryobiological storage and transportation, securing supply for the growing C&GT market[225]. - The company has established strategic alliances with major logistics providers, including FedEx, DHL, and UPS, to integrate advanced cryogenic logistics solutions[215]. - The Cryoportal Logistics Management Platform provides comprehensive shipment management, including near real-time tracking and regulatory compliance[220]. - The Chain of Compliance® solution introduced in 2018 sets a new industry standard for traceability in the C&GT market[221]. - The company is focused on continuous innovation to develop products that address unmet needs in the global supply chain of the C&GT market[213]. Expenses and Financial Management - Selling, general and administrative expenses increased by $14.3 million, or 200.7%, compared to the first quarter of 2020, primarily due to acquisitions[247]. - Engineering and development expenses increased by $2.6 million, or 148.4%, for the three months ended March 31, 2021, compared to the same period in 2020, primarily due to consulting and development costs[249]. - Interest expense rose by $1.2 million for the three months ended March 31, 2021, compared to the same period in 2020, attributed to interest on convertible senior notes[250]. - The provision for income taxes increased by $1.0 million for the three months ended March 31, 2021, with an effective tax rate of negative 41.7% for U.S. earnings[252]. Cash Flow and Capital Management - As of March 31, 2021, the company had cash and cash equivalents of $85.5 million and short-term investments of $267.7 million, with working capital of $381.9 million[259]. - Net cash used in investing activities was $215.4 million during the three months ended March 31, 2021, primarily due to the purchase of short-term investments[261]. - Net cash provided by financing activities totaled $271.4 million during the three months ended March 31, 2021, mainly from net proceeds of $269.8 million from a public offering[262]. - The company recognizes potential need for additional capital to fund operations and acquisitions until sustained profitable operations are achieved[263]. - Foreign exchange risk related to cash and cash equivalents as of March 31, 2021, indicates that a 5%, 10%, and 20% adverse change would result in declines of $0.8 million, $1.5 million, and $3.1 million, respectively[268]. Impact of COVID-19 - The company continues to monitor the evolving situation caused by the COVID-19 pandemic, which has temporarily impacted revenue growth[234].

Cryoport, Inc. (NASDAQ:CYRX) Q1 2021 Results Conference Call May 4, 2021 5:00 PM ET Company Participants Todd Fromer - Managing Partner, KCSA Jerrell Shelton - CEO Robert Stefanovich - CFO Dr. Mark Sawicki - Chief Scientific Officer Thomas Heinzen - VP, Corporate Development and IR Conference Call Participants Matt Andrews - Jefferies Andrew D’Silva - B. Riley Paul Knight - KeyBanc David Saxon - Needham John Sourbeer - UBS Richard Baldry - ROTH Capital Partners Operator Thank you for standing by. This is th ...